Share your videos with the world

Sign Up | Log In | Help  

   
 
Related Tags: health  heart  abbott  fda  valve  doctors  healthcare  children  multivu  8280551  sanofi  vaccines  health  treatment  fluzone  flu  fda  medical  healthcare  multivu  8081151  health  medical  device  3d  fda  gore  procedure  stroke  heart  multivu  8301551  fda  pregnant  women  listeriosis  foodborne  disease  health  hispanic  newborn  multivu  7953451  adenocarcinoma  appendix  cancer  patients  health  immunotherapy  dendritic  cell  vaccine  multivu  64654  food  childhood  obesity  fda  health  kids  overweight  nutrition  safety  multivu  7770751  delta  technology  health  medtech  medical  fda  lithotripter  new  healthcare  multivu  8134451  hearing  fda  loss  hearing  aid  cochlear  limited  kanso  style  discrete  multivu  7658352  aacr  survey  cancer  research  research  national  institutes  health  fda  federal  funding  multivu  7613551  joy  dance  ballroom  dance  lessons  eisai  belviq  lorcaserin  hcl  chronic  weight  management  obesity  overweight  loss  diet  multivu  7161051  ytica  limited  pericoach  women  pelvic  bladder  health  kegel  muscle  exercise  training  medical  device  multivu  7543451 
Search // fda
Results 61-72 of 82 for ' fda ' (0 seconds)
Dornier MedTech® America, a global medical device company and the pioneer of Extracorporeal Shock Wave Lithotripsy (ESWL®), has received FDA clearance to market the Delta® III. This is the latest generation of the world’s best-selling and most clinically cited lithotripter, the Delta II. To view the multimedia release go to: https://www.multivu.com/players/English/8134451-dornier-medtech-delta-iii-kidney-stone-lithotripter/
Categories // Miscellaneous 
Added: 2896 days ago by MultiVuVideos
Runtime: 2m4s | Views: 985 | Comments: 1
Not yet rated
 

 

 

Cochlear Limited (ASX: COH), the global leader in implantable hearing solutions, announces today it has received U.S. Food and Drug Administration (FDA) approval for its newest innovative hearing loss solution, Kanso. The Kanso Sound Processor provides a distinct new way for cochlear implant users to hear. Unlike most hearing aids and current cochlear implant sound processors that are worn on the ear, Kanso is a small, off-the-ear hearing device that provides a more discreet hearing solution and delivers the same hearing experience as a behind-the-ear sound processor. The name Kanso is a Japanese word for ‘simplicity,’ and it was selected in recognition of Kanso’s all-in-one design. The Kanso Sound Processor features a single on/off button with no cables so it is easy to use. It is worn on the user’s head with nothing behind the ear, adding greater comfort for those with glasses, and it can be easily hidden under or blended within a user’s hair. To view the multimedia release go to: http://www.multivu.com/players/English/7658352-cochlear-kanso-fda-approval/
Categories // Miscellaneous 
Added: 3205 days ago by MultiVuVideos
Runtime: 1m51s | Views: 974 | Comments: 0
Not yet rated
 

 

 

Nearly three in four American voters (74 percent) favor increasing federal funding for cancer research, according to the results of a new national survey conducted on behalf of the American Association for Cancer Research (AACR). The survey results were released today in conjunction with the AACR’s fifth annual Cancer Progress Report. The report highlights how federally funded research can power progress against cancer and urges Congress and the administration to implement a strategy for providing annual budget increases of at least 7 percent for the National Institutes of Health (NIH), National Cancer Institute (NCI), and U.S. Food and Drug Administration (FDA) in fiscal year 2016 and thereafter. The national survey, which was conducted by Hart Research Associates and Public Opinion Strategies, shows that five out of every six voters recognize what the AACR Cancer Progress Report 2015 details: that progress is being made against cancer. To view the multimedia release go to: http://www.multivu.com/players/English/7613551-aacr-cancer-research-survey/
Categories // Miscellaneous 
Added: 3561 days ago by MultiVuVideos
Runtime: 3m23s | Views: 962 | Comments: 0
Not yet rated
 

 

 

Eisai Inc. today announced the launch of a new national television advertising campaign for BELVIQ® (lorcaserin HCl) CIV, an FDA-approved prescription therapy for chronic weight management. The advertisement will air on numerous channels including Lifetime, Oxygen and AMC. The spot illustrates the struggles many people face when they are trying to lose or control their weight. BELVIQ is presented as a targeted approach to weight loss, that, when combined with diet and increased activity, may help some patients lose weight and keep it off. To view the Multimedia News Release, go to http://www.multivu.com/mnr/7161051-eisai-launches-national-television-campaign-belviq-lorcaserin-hcl-civ
Categories // Business 
Added: 4080 days ago by MultiVuVideos
Runtime: 2m1s | Views: 945 | Comments: 1
Not yet rated
 

 

 

The millions of women who experience bladder leakage now have a new option to strengthen and tone away their problem instead of covering it up with pads. The PeriCoach System is a discreet device and smartphone app that helps women perform at-home pelvic floor muscle training, exercises recommended by the American College of Physicians as first-line treatment for urinary incontinence. PeriCoach is the only system that includes a web portal allowing clinicians to remotely monitor their patients’ progress. To view the Multimedia News Release, go http://www.multivu.com/players/English/7543451-pericoach-fda-approval/
Categories // People and Blog 
Added: 3646 days ago by MultiVuVideos
Runtime: 1m11s | Views: 940 | Comments: 1
Not yet rated
 

 

 

Federally funded research continues to spur progress against cancer; however, accelerating the pace of progress will require robust, sustained, and predictable annual funding increases for the National Institutes of Health (NIH), the National Cancer Institute (NCI), and the Food and Drug Administration (FDA). Additionally, strong financial support for the National Cancer Moonshot Initiative is required, according to the sixth annual American Association for Cancer Research (AACR) Cancer Progress Report, released today. One of the most exciting new approaches to cancer treatment is cancer immunotherapy. As detailed in the report, the utility of immunotherapy is expanding rapidly. For example, on Aug. 1, 2015, one class of immunotherapeutics, checkpoint inhibitors, was initially approved for just two types of cancer—melanoma and lung cancer. As of Sept. 1, 2016, checkpoint inhibitors have been approved for treating six types of cancer—bladder cancer, head and neck cancer, Hodgkin lymphoma, kidney cancer, lung cancer, and melanoma. To view the multimedia release go to: http://www.multivu.com/players/English/7911951-aacr-2016-cancer-progress-report/
Categories // Miscellaneous 
Added: 3191 days ago by MultiVuVideos
Runtime: 1m23s | Views: 940 | Comments: 0
Not yet rated
 

 

 

The egg has been regarded as a symbol of new life and has been associated with springtime celebrations, such as Easter and Passover, for many centuries. But, even during festive occasions, eggs can cause food poisoning (also called foodborne illness). That’s why the U.S. Food and Drug Administration reminds consumers to follow safe food handling practices when buying, storing, preparing, and serving eggs or foods that contain them during their springtime celebrations and throughout the year. To view the multimedia release go to: http://www.multivu.com/players/English/7790251-fda-egg-safety/
Categories // Miscellaneous 
Added: 3373 days ago by MultiVuVideos
Runtime: 2m51s | Views: 940 | Comments: 0
Not yet rated
 

 

 

Federally funded research that provides a deep understanding of cancer is spurring advances against many types of the disease. With a strong bipartisan commitment from Congress to keep investment in biomedical research a national priority, we can accelerate our pace of progress and save more lives from cancer, according to the seventh annual American Association for Cancer Research (AACR) Cancer Progress Report, released today. Basic research in the fields of immunology and cancer genetics has recently been harnessed to develop two new forms of cancer treatment: immunotherapy and precision medicine. As detailed in the report, the utility of these treatments is expanding rapidly. In May 2017, the U.S. Food and Drug Administration (FDA) heralded a new dawn for precision medicine when it approved the immunotherapeutic pembrolizumab (Keytruda) for treating patients with any solid tumor harboring specific genetic characteristics. This is the first anticancer therapeutic approved based on cancer biomarkers rather than the location in the body where the cancer originated. To view the multimedia release go to: https://www.multivu.com/players/English/8155051-aacr-cancer-progress-report-2017/
Categories // Miscellaneous 
Added: 2833 days ago by MultiVuVideos
Runtime: 1m0s | Views: 933 | Comments: 3
Not yet rated
 

 

 

Cancer Treatment Centers of America® (CTCA), a national network of comprehensive cancer care hospitals and outpatient care centers, and Foundation Medicine, a leading molecular insights company that recently received FDA approval for its FoundationOne CDx™ genomic test, today announced the launch of a collaborative educational campaign designed to heighten awareness of the promise of precision medicine and the role that advanced genomic testing plays in helping identify treatments best suited for individual patients. To view the multimedia release go to: https://www.multivu.com/players/English/8295651-cancer-treatment-centers-of-america-foundation-medicine-precision-cancer-treatment/
Categories // Miscellaneous 
Added: 2625 days ago by MultiVuVideos
Runtime: 0m27s | Views: 898 | Comments: 4
Not yet rated
 

 

 

Boston Scientific (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval for the SYNERGY™ Bioabsorbable Polymer Drug-Eluting Stent System (BP-DES) for the treatment of coronary artery disease. With this FDA approval, Boston Scientific will commence commercialization of the first and only BP-DES in the U.S. Notably, both the drug coating and the polymer – which modulates drug release – are fully absorbed shortly after drug elution is complete at three months. The SYNERGY Stent provides synchronized drug and polymer absorption. It is designed to enable more rapid and complete arterial healing, and to thereby reduce the risk of complications associated with long-term polymer exposure compared to currently-used drug-eluting stents (DES) with permanent polymers. To view the multimedia release go to: http://www.multivu.com/players/English/7223456-boston-scientific-fda-approval-synergy/
Categories // Science and Technology 
Added: 3542 days ago by MultiVuVideos
Runtime: 0m45s | Views: 900 | Comments: 2
Not yet rated
 

 

 

The American Society for Aesthetic Plastic Surgery (ASAPS), is hosting a panel discussion about the latest best practices and uses for injectables including the newest FDA-approved options at The Aesthetic Meeting today in Montreal, Quebec Canada. The panel discussed the latest advances, including the ways various dermal fillers can be utilized to produce optimal results for targeted areas. There are thirteen FDA-approved dermal fillers on the market to-date, providing aesthetic plastic surgeons with the ability to customize anti-aging treatments to patients’ needs. “The filler choices are dictated by a patient’s unique aging pattern, the anatomical area to be treated and physiochemical properties,” explains ASAPS member, Dr. Z. Paul Lorenc. To view the Multimedia News Release, go to http://www.multivu.com/players/English/7310753-asaps-facial-rejuvenation-injectables/
Categories // People and Blog 
Added: 3682 days ago by MultiVuVideos
Runtime: 0m28s | Views: 895 | Comments: 1
Not yet rated
 

 

 

EnteroMedics Inc. (NASDAQ: ETRM) today announced that the U.S. Food and Drug Administration (FDA) has approved VBLOC® vagal blocking therapy, delivered via the Maestro® System, for the treatment of adult patients with obesity who have a Body Mass Index (BMI) of at least 40 to 45 kg/m2, or a BMI of at least 35 to 39.9 kg/m2 with a related health condition such as high blood pressure or high cholesterol levels, and who have tried to lose weight in a supervised weight management program within the past five years. The Maestro System is the first new medical device to be approved by the FDA for obesity in over ten years. EnteroMedics anticipates that the device will be available, on a limited basis, at select Bariatric Centers of Excellence in the U.S. this year. The Maestro System has received CE Mark and is listed on the Australian Register of Therapeutic Goods. To view the Multimedia News Release, go to http://www.multivu.com/players/English/7269351-enteromedics-fda-approval-vbloc-maestro-system-weight-loss-device/
Added: 3806 days ago by MultiVuVideos
Runtime: 0m24s | Views: 864 | Comments: 2
Not yet rated
 

 

 

Page 6 of 7  |  Go to page     |  ««FIRST «Previous  Next» LAST»»



About Us   |   Help  |   Advertise on ClipMoon   |   Terms of Use   |   Privacy Policy   |   Copyright   |   Contact   |   Link us   |   RSS 
Copyright © 2007-2025 ClipMoon.com. All rights reserved.